Sofregen Medical Inc., a Medford, MA-based company advancing silk-based medical technologies to address soft tissue defects, raised $6.2m in Series A financing.
Backers included Polaris Partners and other founding investors.
Founded in 2014 to advance technology developed at Tufts University and the University of Pittsburgh and led by Howard Weisman, Chairman, Sofregen uses silk, nature’s healing fiber, in a variety of forms to enable physicians to address soft tissue defects, restoring function and cosmetic appearance for medical and aesthetic patients worldwide.
The company, which has a variety of silk-based innovations currently in development, will use the funding to further advance its platform.
It had previously raised $1.6m from seed investors and has also agreed to terms on $3.5m in bank debt financing, which brought total funding to $11.3m.